Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Faeth Therapeutics, Inc. Common Stock

FTH

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Last trade $9.04
Day change -$0.24 (-2.59%)
Day range $8.56 – $9.58
Volume 529,390
Market cap $240M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$239.83M
Price / earnings
—
Price / book
1.49×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.04×

Profitability

Earnings per share
-$8.18
Return on assets
-118.11%
Return on equity
-131.2%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.12×
Quick ratio
16.12×
Cash ratio
1.29×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FTH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$10.35M$9.21M
Research and development$11.74M$9.18M
Total operating expenses$22.09M$18.39M
Operating income-$22.09M-$18.39M
Interest expense$0$0
Income before taxes-$20.4M-$16.01M
Income taxes$0$0
Net income-$20.4M-$16.01M
Net income attributable to common shareholders-$20.4M-$16.01M
EBITDA-$22.07M-$18.36M
Basic earnings per share-$0.79-$2.84
Diluted earnings per share-$0.79-$2.84

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.